Breast Cancer

Breast cancer is well screened, yet US stage IV incidence rose 1.2% a year in 2010 to 2021, and the benefit of each new adjuvant therapy concentrates in subgroups not yet identifiable in advance.

About Breast Cancer

In numbers

An estimated 321,910 women and 2,670 men in the USA are diagnosed with invasive breast cancer each year, and about 57,000 people in the UK. Receptor status (HR-positive/HER2-negative around 70%, triple-negative 15%, HER2-positive 15%) guides more than 90% of treatment choice.
NCI SEER reports five-year relative survival of 100% for localised breast cancer and 33.8% once it has spread. Even so, US stage IV incidence rose 1.2% a year in 2010 to 2021 while stage I to III barely moved (JAMA Network Open, 2026, more than 760,000 diagnoses).
Screening reaches the people it invites who attend: about three in ten women invited in England do not attend (NHS England), and incidence is rising under 50, mostly below screening age (CA: A Cancer Journal for Clinicians, 2024).

Special details

The WHO Global Breast Cancer Initiative targets at least 60% of invasive breast cancers diagnosed at stage I or II. WHO estimates five-year survival at 41% in low-income and 87% in high-income countries (July 2026).
After first-line treatment, distant recurrence risk in HR-positive disease is 10% to 41% over 5 to 20 years, and more than 140,000 US women live with metastatic breast cancer, most first diagnosed at an earlier stage (NEJM, 2017; JNCI, 2022).
Adjuvant abemaciclib added 7.6 points of five-year invasive disease-free survival (monarchE) and ribociclib 4.5 points (NATALEE), with benefit concentrated in subgroups not yet identifiable in advance. One in three women on endocrine therapy has stopped by year five (The Breast, 2022).

Signs and symptoms of Breast Cancer

Screening diagnoses most cases, so the gaps lie upstream, in women outside programmes, and downstream, in subtype, biomarker and BRCA testing that has not kept pace with treatment.

Breast lump

The most common presentation outside screening, often without discomfort in early disease.

Skin and nipple changes

Dimpling, retraction, redness, warmth or peau d'orange, which can resemble mastitis in inflammatory breast cancer.

Nipple discharge

Unilateral, spontaneous, and either bloody or clear.

Axillary lymph node swelling

A sign of regional spread that may be noticed before a breast change.

Symptoms of metastatic disease

These depend on which organs the cancer has reached.

Key challenges from product development to launch

Strategy and Business

The wrong disease or indication selected for investment
Indications tackled in the wrong order due to shaky success estimates
R&D returns slipping below the cost of capital

Clinical Development

Trials delayed by low patient recruitment
High screen-failure rates that raise trial cost
Mixed cohorts that make the signals difficult to detect

HEOR, Access & Value

A value case that arrives too late or is underdeveloped
Eligible population under-counted, budget-impact case unsubstantiated
Approved by the regulator, delayed at HTA

Medical Affairs

Fragmented, differently-coded healthcare data
Diagnostic delay that is long and unequal
No shared evidence base across functions

Launch and Commercial

Launch planned without a view of the number of findable patients
Targeting too broad a population slows early uptake
RWE started too late to build the case

How Volv Global Helps

Strategy and Business

The earliest pipeline decisions carry lasting consequences: the wrong indication chosen, indications pursued in the wrong order, or capital committed where expected returns already trail its cost. Mistakes made this early are expensive to correct later.

inTrigue

Finds the true reachable population per candidate, so indication choices rest on evidence.

volv.global/finding-patients

inFlow

Adds probability-of-success and outcome evidence to help prioritise the pipeline.

volv.global/predict-patient-outcomes

Clinical Development

When patients cannot be found, recruitment stalls and the burn rate climbs. High screen-failure rates add further cost and delay, and a mixed cohort makes the results harder to interpret.

inTrigue

Finds the undiagnosed and mis-coded patients conventional feasibility misses, widening the recruitable pool.

volv.global/finding-patients

inCare

Surfaces diagnosed-but-hidden, trial-eligible patients already in the data, so sites enrol faster.

volv.global/stratifying-patient-cohorts

inFlow

Predicts who will progress or respond, enriching the cohort so the signal is not diluted.

volv.global/predict-patient-outcomes

HEOR, Access & Value

Without strong, timely evidence, payers can restrict access or cut the price. An under-characterised population weakens the budget case, and HTA approval demands more evidence than regulatory approval alone.

inFlow

Generates the real-world evidence and outcomes payers ask for, ahead of the submission deadline.

volv.global/predict-patient-outcomes

inTrigue

Finds the undiagnosed patients missing from the count, so the eligible population holds up under scrutiny.

volv.global/finding-patients

inCare

Surfaces the diagnosed-but-eligible patients who expand the eligible population count.

volv.global/stratifying-patient-cohorts

Medical Affairs

Healthcare data is fragmented across markets, so evidence has to be rebuilt market by market, slowing decisions. Time to an accurate diagnosis varies by who the patient is and where they are treated.

inTrigue

Works across fragmented, differently-coded data by design, so insight holds up country to country without a rebuild.

volv.global/finding-patients

inAdvance

Detects patients ahead of typical diagnosis, closing the gap in awareness and pathway that drives unequal delay.

volv.global/earlier-detection

Launch and Commercial

A launch planned without a view of findable patients is poorly resourced from day one. Targeting too broad a population slows early uptake, and real-world evidence gathered too late leaves little time to build a strong access dossier.